AmacaThera Announces Successful Phase 1 Results of First-in-Human Study with AMT-143

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, announced results from its Phase 1 clinical trial of AMT-143, an innovative, non-opioid anesthetic, formulated with the company's patented AmacaGel™ platform, demonstrating sustained anesthetic release out to 14 days. AMT-143 is intended to deliver extended, localized pain relief without the need for opioids, significantly reducing the risks associated with opioid addiction and side effects in order to improve patient outcomes post-surgery.

AmacaThera is an OBIO® member, an alumnus of all OBIO® programs, and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

New X-ray Imaging Technique Improves Diagnostic Confidence for Early Identification of Heart Disease Risk
Next

Zucara Therapeutics Announces Strategic Investment from Sanofi as Part of US$20 M Series B Financing